The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Ähnliche Einträge

• The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
  von: Tseng, Jeng-Sen, et al.
  Veröffentlicht: (2016)
• Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
  von: Su, Kang-Yi, et al.
  Veröffentlicht: (2018)
• The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
  von: Huang, Yen-Hsiang, et al.
  Veröffentlicht: (2021)
• Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients
  von: Huang, Yen-Hsiang, et al.
  Veröffentlicht: (2016)
• Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
  von: Tseng, Jeng-Sen, et al.
  Veröffentlicht: (2018)